おすすめの製品
由来生物
rabbit
品質水準
100
500
結合体
unconjugated
抗体製品の状態
culture supernatant
抗体製品タイプ
primary antibodies
クローン
SP133, monoclonal
詳細
For In Vitro Diagnostic Use in Select Regions (See Chart)
フォーム
buffered aqueous solution
化学種の反応性
human
包装
vial of 0.1 mL concentrate (350R-14)
vial of 0.5 mL concentrate (350R-15)
bottle of 1.0 mL predilute (350R-17)
vial of 1.0 mL concentrate (350R-16)
bottle of 7.0 mL predilute (350R-18)
メーカー/製品名
Cell Marque™
テクニック
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500
アイソタイプ
IgG
コントロール
DLBCL, lymph node, tonsil
輸送温度
wet ice
保管温度
2-8°C
視覚化
nuclear
遺伝子情報
human ... FOXP1(27086)
詳細
Diffuse large B-cell lymphoma (DLBCL) represents different clinicopathologic entities which are difficult to separate using standard techniques. From the clinical standpoint, the introduction of immunochemotherapy in the treatment of DLBCL has dramatically improved the outcome of these patients compared with chemotherapy alone. Gene expression profiling (GEP) studies have shown that DLBCL can be reproducibly divided into the important subtypes of germinal center B-cell–like (GCB), activated B-cell–like (ABC), and unclassified DLBCL. It is beneficial to translate the GEP classification into protein expression by tumor cells through immunohistochemical (IHC) staining of formalin-fixed, paraffin-embedded tissues. A panel of antibodies: CD10, BCL6, MUM1/IRF4, GCET1, FoxP1, LMO2, and BCL2 has been used to determine GCB or ABC and each has different percentage thresholds for positive staining. Choi et al. demonstrated that the cases positive for GCET1 (≥ 80% of tumor cells) and MUM1/IRF4 (≥ 80%) and/or FoxP1 (≥ 80%) or negative for CD10 and BCL6 (≤ 30%) were assigned to the group. The cases positive for CD10 (≥ 30%), GCET1 (≥ 80%) without MUM1 expression, or positive for BCL6 without FoxP1 expression were classified as GCB. This study indicated the importance of FoxP1 in the subclassification of DLBCL. Choi et al then modified their approach to DLBCL subclassification by focusing on FoxP1. The tumors that are positive for both FoxP1 and GCET1 are assigned to GCB subgroup, but, if FoxP1 is positive and GCET1 is negative, the tumors belong to the ABC phenotype. If a case is FoxP1 negative but MUM-1/IRF4 positive, it still belongs to the ABC phenotype as long as CD10 is not expressed. This modified method emphasized the role of FoxP1, MUM1/IRF4, and GCET1 in the subclassification of DLBCL. The Choi′s algorithm had a very high concordance with the GEP results (87%). Therefore, FoxP1 is useful in subclassification of DLBCL and a high cutoff (≥80%) for FoxP1 is needed to achieve high specificity for the ABC subtype.
品質
IVD | IVD | IVD | RUO |
関連事項
FoxP1 Positive Control Slides, Product No. 350S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
物理的形状
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
調製ノート
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
その他情報
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
法的情報
Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
最新バージョンのいずれかを選択してください:
Further studies on biosynthesis of erythropoietin.
Indian journal of biochemistry & biophysics, 18(4), 241-244 (1981-08-01)
The New England journal of medicine, 346(25), 1937-1947 (2002-06-21)
The survival of patients with diffuse large-B-cell lymphoma after chemotherapy is influenced by molecular features of the tumors. We used the gene-expression profiles of these lymphomas to develop a molecular predictor of survival. Biopsy samples of diffuse large-B-cell lymphoma from
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29(2), 200-207 (2010-12-08)
Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic groups based on the cell of origin of the tumor as determined by microarray analysis. Various immunohistochemical algorithms have been developed to replicate these microarray results and/or stratify
Swerdlow, SH et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Geneva: World Health Organization; 2008.
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue (2008)
Annals of oncology : official journal of the European Society for Medical Oncology, 17 Suppl 4, iv31-iv32 (2006-05-17)
The multicentre phase III CORAL study aims to guide choice of salvage chemotherapy in diffuse large B-cell lymphoma (DLBCL) and assess the role of rituximab maintenance after autologous stem cell transplantation (ASCT). Patients are first randomised between ICE (ifosfamide, carboplatin
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)